|
|
Each tablet contains
Composition
Mycophenolate Mofetil
...................................................500 mg
Indications
Mycophenolate is indicated for the prophylaxis of organ rejection
in patients receiving allogeneic renal, cardiac or hepatic
transplants. Mycophenolate should be used concomitantly with
cyclosporine and corticosteroids.
Description
The salvage pathway of purine synthesis in lymphocytes is less
active than the de novo synthesis of purines. Inosine
monophosphate is converted to guanosine monophosphate by inosine
monophosphate dehydrogenase. During T-cell activation, the
activity of both types I and II inosine monophosphate
dehydrogenase enzymes increases by tenfold. Mycophenolate mofetil
is converted in the liver by ester hydrolysis to mycophenolic
acid, which in turn non-competitively and reversibly inhibits
types I and II inosine monophosphate dehydrogenase activity during
DNA synthesis in the S phase of the cell cycle. In the salvage
pathway, guanine is converted to guanine monophosphate by the
enzyme hypoxanthine-guanine phosphoribosyltransferase.
Dosage
A dose of 1 g administered orally twice a day (daily dose of 2 g)
is recommended for use in renal transplant patients or as per the
physician’s advice.
Presentations
10 tablets
|
Quality
